{"title": "Pfizer shares downgraded as patent expirations loom", "selftext": "From MarketWatch:\n\nPfizer Inc. shares were downgraded to market perform from outperform at TD Cowen on Thursday, as analysts see upcoming patent expirations and shaky confidence in the drugmaker‚Äôs management clouding the outlook. Despite a brutal 2023, when the stock dropped more than 40%, it‚Äôs ‚Äútough to pound the table even from these levels,‚Äù the analysts wrote, adding that expected strong earnings growth through 2026 will be weighed down longer term by losses of market exclusivity on key drugs like the blood thinner Eliquis and breast cancer treatment Ibrance. The analysts said their confidence in Pfizer management is ‚Äúnot the highest,‚Äù noting that much of the company‚Äôs recent guidance has proven overly optimistic and decisions to divest assets through Roivant Sciences Ltd. and Cerevel Therapeutics Holdings Inc. look questionable given the values placed on those assets by competitors. Pfizer shares fell 0.2% premarket on Thursday and are down 40.7% over the past 12 months, while the S&P 500 has gained 22%.", "id": "18yrjih", "created_utc": 1704411107.0, "score": 159, "upvote_ratio": 0.92, "num_comments": 82, "comments": [{"body": "I wish I were smart enough to confidently wade into the healthcare sector. Alas, I am not. \n\nKeeping up with rights, patents, development, trials, etc? That‚Äôs difficult when I have the attention span of a coconut.", "score": 137, "replies": [{"body": "The only pharma name I own is vertex, which up until recently basically had one medication, so it was easy to figure out their patent protection. \n\nAn interesting play I own is MEDP. They do outsourced clinical trials for pharma companies. They basically win as long as new drugs are being developed.", "score": 29, "replies": [{"body": "I have vertex, Lilly and novo nordisk.  They have all performed well.", "score": 9, "replies": [{"body": "You have Lilly but not Verve Therapeutics??  Lilly has clearly cast their umbrella over Verve and their gene editing ( not CRIPR) approach to curing High Cholesterol and wiping out the Statin market.", "score": 1, "replies": []}]}, {"body": "Who‚Äôs their competitor?", "score": 3, "replies": [{"body": "Labcorp, IQVIA, ICON, Parexel, PPD, Syneos‚Ä¶those are some of the other big clinical research organizations", "score": 8, "replies": []}]}, {"body": "As a chemistry student, I really appreciate Vertex for what they do but it's also kind of sad that they can hold an orphan drug hostage like that.\n\nIt feels like every third current organic chemistry publication demonstrates how their method could be used to make Ivacaftor but nobody can commercialize that because of IP. You can make it in a scientific lab but you can't sell it.", "score": 2, "replies": [{"body": "Yeah, it's always the debate with pharma. They need a reward for developing medications and we grant them exclusively on their discovery as a reward and incentive. However, the costs to consumers are high initially. It's tough, but if we take away the financial incentive to innovate, will we be as innovative?", "score": 2, "replies": [{"body": "Research, especially in bioscience, is just a bottomless pit for money. You could always do more with more money, more people and more time but all of those factors tend to be very limited.\n\nPublic grant funding can at least make pharmaceutical R&D more appetizing for companies. For example, the German federal government almost fully funded the original development of the Biontech/Pfizer vaccine. Biontech later returned the favor by singlehandedly paying off the debt of the city of Mainz with their corporate tax bill.\n\nCollective negotiation via public health insurance can then push down prices once the R&D costs are more than paid off and only operational costs are left.", "score": 1, "replies": [{"body": "Remember that R&D cost has to include a MASSIVE risk premium for failure too. If a company researches 10 drugs, and only 1 makes it to market, the R&D cost is the cost of all 10 drugs.", "score": 1, "replies": []}]}]}]}, {"body": "Medpace are terrible at what they do (we sadly bought a company and were tied to them to operationalize a clinical trial for us). Can‚Äôt comment on them as a stock but there are other, better CROs out there that do the same thing much better.", "score": 2, "replies": [{"body": "What don‚Äôt you like about them and who do you think is better? I have limited experience with them but I didn‚Äôt have a great time when I did.", "score": 3, "replies": [{"body": "They don‚Äôt know what they are doing. They don‚Äôt attract the best talent as their office is in like Cincinnati or something and they don‚Äôt pay well. The big CROs are IQVIA, Labcorp, Parexel, and Icon. Large companies usually want to enter into single CRO agreements and that usually leads to needing the largest CRO possible (for global reach)\n\nhttps://www.proclinical.com/blogs/2023-4/top-10-cros-to-watch-in-2023", "score": 6, "replies": [{"body": "[deleted]", "score": 2, "replies": [{"body": "I‚Äôm an exec (VP Clin Dev) at one of the biggest pharmas in the world and developed a single source CRO partnership for one of the largest biotechs in the world in my previous job. A lot of the medpace people tend to live in Ohio other than the CRAs. Labcorp and Fortrea are the same thing to me. PPD don‚Äôt exist as are part of Thermo so they don‚Äôt count.\n\nAs I said, I don‚Äôt know about medpace financials, but they are awful at what they do. They can‚Äôt do rare disease phase 3 as they don‚Äôt have the global reach so they are stuck doing small stuff or non rare indications (which are drying up)\n\nI develop drugs for a living, you make slides to help people like me make decisions, we are not the same.", "score": 1, "replies": [{"body": "[deleted]", "score": 1, "replies": [{"body": "I am on patents as an inventor for several drugs each worth tens of billions of dollars. People like you don‚Äôt ‚Äúfind drugs‚Äù for people in my role.\n\nAlso a lot of the big guys you mention (including current company) don‚Äôt even use CROs for these services at the moment, we have swung in the direction of insourced CRAs. As you know this is cyclic and has happened before and will go the other way again one day.\n\nSingle source CRO (or maybe 2x CROs) is a good idea for companies with multiple phase 3 programs, as the systems and the SOPs are locked down and staff can seamlessly move from project to project. Medpace would never get a look in as a preferred supplier for any big company I don‚Äôt believe.\n\nAnyway, Medpace, in my experience, are way behind other players from a quality standpoint, financially, I cannot comment.", "score": 3, "replies": []}]}]}]}, {"body": "Thanks for this! I just finished doing a checklist of medp when I saw this thread. \n\nI just spent a couple of hours just comparing medp, tmo, iClr and iqv.\n\n\nFrom an investment attractiveness perspective (to me naturally), medp is the most attractive, followed by tmo and then iqv and lastly iClr.\n\nIclr has the worst efficiency ratios and the worst growth. \n\nIqv has the biggest dilution at 46% in the last ten years and the biggest debt load ( takes 11 yrs of net income to pay off the lt debt)\n\nIt is no coincidence that tmo and medp have executives with high ownership of the company.\n\nMedp is attractive except for the price, so I am putting this on the watchlist l.", "score": 1, "replies": []}]}]}]}, {"body": "I love picks and shovels plays. Doesn't matter who wins as long as they keep playing thr game.", "score": 2, "replies": []}, {"body": "MEDP sounds like a very smart way to be in the sector. That business model is a bit like a healthcare equivalent of a market maker in financials in that they profit from activity. That‚Äôs intriguing.", "score": 1, "replies": [{"body": "No, id consider them more like an operator (vs an oil company) in that sector. They provide a service that the oil company (in our case Pharma company) need, but don‚Äôt own the oil (drugs) themselves.", "score": 3, "replies": [{"body": "Fair frame up!", "score": 1, "replies": []}]}]}]}, {"body": "Please explain what is the attention span of a coconut", "score": 2, "replies": []}, {"body": "If you are interested, Shkreli has a lot of good Youtube content on the subject.", "score": 2, "replies": [{"body": "I occasionally watch his videos for fun. However, I don‚Äôt feel a need to be active in the space.", "score": 3, "replies": []}]}, {"body": "I'm in pharma and it's definitely challenging. But I'm making it and I'll figure it out eventually. You can too!", "score": 1, "replies": []}, {"body": "All you have to know is that most trials fail or at least don't get to the finish line with an FDA approval. If you're not from that industry with some insider knowledge it's better to stay away.", "score": 1, "replies": []}, {"body": "My feelings are similar, so I bought ThermoFisher who supply a lot of machinery in labs etc", "score": 1, "replies": []}]}, {"body": "So to state the obvious - TD Cowen was rating the stock at outperform all the way down.  Now that it is at the bottom, they downgrade it.", "score": 39, "replies": [{"body": "Yeah sketchy af.", "score": 13, "replies": []}]}, {"body": "what I don't get is why after successfully creating mrna vaccines for the first time ever, all that investment and knowledge seems to have a market value of zero now. As though mrna science only applied to covid. \n\nMeanwhile, Elon Musk can blow up rockets and people are dying to throw money at him in the hopes that one day he takes them to mars. \n\nOdds are Pfizer will save your life before Elon does. \n\nAnyway, I think pfizer had two massive losses...no one wants any more vaccines for covid and they missed out in the weight loss craze. \n\nBut it's hard to imagine Pfizer is going to just fade away into obscurity over time.", "score": 68, "replies": [{"body": "Pfizer is still valued at $164 billion. The market isn't pricing it for bankruptcy or obscurity. Although, I'm seeing a payout ratio of 91% so I would think the dividend is in danger. That combined with patent cliff issues might make it a market trailing investment for awhile. I have no position though. Technically it looks to be bottoming. It didn't seem to move much on this downgrade (so far) which sort of supports that.", "score": 12, "replies": [{"body": "Check out their FCF payout....", "score": 2, "replies": []}]}, {"body": "> cost - something most investors don‚Äôt think about.  You can never be wrong if you take a profit and sometimes a loss is worth taking to get out of dead money.\n\nTHIS!!! BE GREEDY WHEN OTHERS ARE FEARFUL. 6% dividend + drip if price falls further. PFE has paid dividends for 64 years. Operational in over 100 countries. Its basically a bond replacement. And once in a decade if they find a drug and price pops I will sell.", "score": 28, "replies": [{"body": "100% agreed. What people don't realize is that PFE makes A LOT more than just a COVID vaccine and a hopeful weight loss med. Go get your children's vaccinations and take a look at the manufacturer of many of them: PFE. Let's not even get started with a variety of cancer meds, IV meds used in the hospital, etc etc etc... the company CASH FLOWS and pays a dividend to its investors. What does Tesla do for me outside of go up and down and trying to time buying and selling it? PFE will  rebound. In the mean time, collect a juicy 6% dividend. Same thing with Verizon...", "score": 17, "replies": [{"body": "So true", "score": 3, "replies": []}]}, {"body": "Look at wags, just cut dividends after 50. Years. Nothing is 100%", "score": 10, "replies": [{"body": "Yes but you could easily see they were paying 90% of their free cash to the dividend. Pfizer doesn't have that problem.", "score": 8, "replies": []}, {"body": "Man if I followed the crowd and the market every time there is a scare I wouldnt be as rich as I am today. I am sure Pfizer will fall a little more before the price stabilizes. My margin of safety allows me to recover the principal + moderate returns (not market beating) this is a slow burning cigarette butt stock at this point and def has some puffs before i dispose of it. Thats all i care about. When its easy money you take it. Same happened with KO the ozempic drove down the price to 53 bucks. These are quality companies that have been around for over 50 years. The know what the fuck they are doing. or they will acquire another company to cover their revenue. I have seen this game play out way too often. And am up 12.5% as we speak. cost basis is 26.14. I can simply sell it today and still have made a profit.", "score": 0, "replies": [{"body": "I don‚Äôt disagree with you. I‚Äôm bullish on Pfizer but there is always risk. I own shares and I got a couple $35 2025 calls that‚Äôs doing well and been selling  some $ 27 and $28 puts at this level.", "score": 1, "replies": []}]}]}, {"body": "Agreed. Loaded at 26.", "score": 3, "replies": []}]}, {"body": "Pfizer will likely remain, though they need to innovate to stay big. Otherwise they'll slowly shrink...pharma is a high stakes game.\n\n\n\nAnd as for Elon he has 2 pros. First of all he's the perfect sucessful man child every edgy teen/loser adult wants to be and they'll happily pay for one of their own to succeed (cult of personality). The second thing is Pfizer promises *longer life as you live it, right now* which is maybe popular for older people. Elon promises a *chance at a totally new life amongst the stars* which is, once again, a dream setting for every loser, lowlife or simply depressed person who thinks their life is a failure in some way. A call to adventure VS a call to 10 years more at a retirement home.", "score": 8, "replies": [{"body": "> A call to adventure VS a call to 10 years more at a retirement home.\n\nFuck thats harsh but hilarious", "score": 4, "replies": []}]}, {"body": "> Meanwhile, Elon Musk can blow up rockets and people are dying to throw money at him in the hopes that one day he takes them to mars. \n\nEven worse, people are willing to throw money at a overpriced taxi tunnel with human drivers as some 'revolutionary transport of the future' just cause Musk is peddling it!", "score": 2, "replies": []}, {"body": "> after successfully creating mrna vaccines for the first time ever, all that investment and knowledge seems to have a market value of zero now.\n\nThe vaccine was created by BNTX, Pfizer was their partner for mass production and testing. Pretty much all the the IP stayed with Biontech.\n\nFrom the [press release](https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-announce-further-details-collaboration) when they announced the collaboration:\n\n>The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on **BioNTech‚Äôs proprietary mRNA vaccine platforms**, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage Pfizer‚Äôs broad expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.\n\n>The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites. BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance.\n\n>During the clinical development stage, BioNTech and its partners will provide clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer will work together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China which is already covered by BioNTech‚Äôs collaboration with Fosun Pharma) upon regulatory approval.", "score": 3, "replies": [{"body": "thanks for this. Good to know. \n\nBut it also seems like Pfizer is pursuing mrna tech both [in-house and through additional partnerships.] (https://www.pfizer.com/science/innovation/mrna-technology#:~:text=Pfizer's%20next%20wave%20of%20mRNA,areas%20of%20rare%20genetic%20diseases.)\n\nIt just seems to me that you have this leading-edge tech that has many potential applications in the future... and Pfizer (and a few others) got to run the biggest mrna experiment ever using almost the entire global population.... and the market basically views that has worthless now (at least pfizers market cap has reverted to pre-covid levels). \n\nJust seems odd to me.", "score": 1, "replies": []}]}, {"body": "People don't value their health.. this starts at the bottom up. A lot of people eat junk food.", "score": 2, "replies": []}, {"body": "SpaceX is doing quite well right now with Starlink and has a huge lead in rocketry.", "score": 2, "replies": []}, {"body": "also mrna vaccine was a major failure they boasted 98% prevention or something and everyone i know with the shot got covid at least once if not multiple times despite booster", "score": -9, "replies": [{"body": "But did they die?", "score": 4, "replies": []}, {"body": "Another company who doesn't just make covid vaccines.", "score": 2, "replies": []}]}, {"body": "IIRC the mRNA technology isn't something new. There hasn't been any proven (besides covid) use for them, so I guess they were priced in. Just the other day I saw the first news (for me at least) of successful trials (not sure which phase) for skin caner prevention using mRNA vaccines. So now that they are getting to the practical stuff and not only theoretical, I guess a boom could come", "score": 1, "replies": []}]}, {"body": "\\-2.2% so what. Got nothing to do with their earnings.", "score": 6, "replies": []}, {"body": "Own a $150k in PFE now. Throughly enjoy the $9k in dividends paid yearly.  Pays my property taxes. Will continue to buy the dips and patiently wait collecting a reliable paycheck. Will exit once it makes sense. 6 months from now or 2 years. Fuck it, doesn't matter.", "score": 11, "replies": []}, {"body": "Oh no. \n\nDid TD Cowen suddenly realise about patent expiry just now?", "score": 8, "replies": []}, {"body": "Nothing shocking about this news.  I‚Äôve said PFE was a value trap for 30+ years.  If you invested in PFE 5 years ago and held through the Covid stock price run you would be down 28.7% - with dividends basically flat.  The 10 year number is basically the same - and I have to imagine worse when adjusted for inflation.  \n\nGood dividend, but the managements pipeline for growth is dependent on buying companies with debt - not a good long term growth model IMO.  The returns prove it.  Lots of well paid employees at shareholders expense with PFE.  \n\nUnless there is a major shift in management and a real plan for growth there are much better opportunities IMO.", "score": 18, "replies": [{"body": "I don't know, seems like an easy 20% to me. Downside fairly limited, strong dividend to give you a bit of buffer, plenty of equity upside and history. Can sell covered calls for a little extra. If I was a betting man, and I am.. PFE will see $33 this year, and I'll collect on covered calls and dividend in the meantime. Easy 20%+.", "score": 6, "replies": []}, {"body": "Well said. I was in for 10+ years and was glade the Covid spike gave me the opportunity to sell and get out with a great profit.", "score": 7, "replies": [{"body": "I‚Äôm glad you took advantage of that price spike. Sitting on a flat / dead money is lost opportunity cost - something most investors don‚Äôt think about.  You can never be wrong if you take a profit and sometimes a loss is worth taking to get out of dead money.", "score": 1, "replies": []}]}, {"body": "They've always stayed relevant through acquisitions. From the articles I've read, buying Seagen doubles their exposure to the oncology wing of medicine and is anticipated to be a net positive on the financials in the next 5 years, not to mention how much that research will catapult the rest of their cancer drug research or the remaining years of its current patents.\n\nRinse and repeat this endlessly as their cash reserves allow and it's not hard to see why Pfizer has survived all this time. Is there better opportunities? Absolutely. But theres also worse choices than Pfizer. They have their hands in a recession proof growth industry (that never seems to stop getting more expensive) and they have a pretty great dividend. All they need to do is cut costs.", "score": 7, "replies": []}]}, {"body": "If it dipped again I ain‚Äôt hesitate to get in. I will buy shit loaded", "score": 5, "replies": []}, {"body": "seems bullish i own 101 shares w DRIP", "score": 2, "replies": []}, {"body": "5.25% div!", "score": 2, "replies": []}, {"body": "Looks like a buying opportunity", "score": 3, "replies": []}, {"body": "I was a bag holder for 2 years. Finally sold my shares at 50% loss. Oh well. Still have 44 shares tho. Gave up hope on P.  \nOn the bright side, I sold LLY today ATH and made $$.", "score": 2, "replies": []}, {"body": "Good buy for 29$", "score": 2, "replies": []}, {"body": "Cowen should be investigated.  This was done intentionally for some reason.  Sketchy as hell.", "score": 2, "replies": []}, {"body": "I wonder if there's going to be a PFE pile on from the various research firms and how low they can drive the share price.  I'm watching closely. I think it might go under $20 per share.  But however low it goes, you have to think the CEO is going to get fired pretty soon.", "score": 1, "replies": []}, {"body": "Fak, else", "score": 0, "replies": []}, {"body": "Meanwhile, people loading up on PFE on r/dividends likes it‚Äôs 2017 AAPL", "score": 0, "replies": []}, {"body": "[removed]", "score": -29, "replies": [{"body": "Do you morons ever get tired of complaining about the pandemic? It isn‚Äôt a personality trait yknow", "score": 1, "replies": []}, {"body": "Off topic:  Not bringing up stocks or the stockmarket.\n\nAlmost any post related to stocks and investment is welcome on r/Stocks, including pre IPO news, futures & forex related to stocks, and geopolitical or corporate events indicating risks; outside this is offtopic and can be removed.\n\nPosts & comments that are purely political, religious (dealing with morality), or focusing on other types of investments not related to stocks such as real estate, crypto, designing websites, or even selling sneakers will be removed.  An example of what wouldn't get removed:  Discussing real estate when related to the ETF VNQ or real estate bubble affecting the stock market.\n\nA full explanation of all /r/stocks rules can be found here: https://www.reddit.com/r/stocks/wiki/rules", "score": 1, "replies": []}]}, {"body": "For some reason I read this as their \"patients \"  expired.. hmm üßê", "score": 1, "replies": []}, {"body": "Eh‚Ä¶ $26.51 cost basis and 32.5 Calls expiry Jan 2025 is still looking very good for me. Ill load up more for the dividends.", "score": 1, "replies": []}, {"body": "Well maybe now we can finally get legal weed...", "score": 1, "replies": []}, {"body": "\"confidence in Pfizer management is ‚Äúnot the highest,‚Äù \n\nI've said this for months on here as people kept trying to pump PFE - they don't have the pipeline and the market doesn't have confidence in them to do a good job going out and spending money to fill it. So you get a stock that at best goes pretty much nowhere over long periods and at worst starts becoming more of a melting ice cube.", "score": 1, "replies": []}, {"body": "This has been known for ever and ABBV faced the same. They just bough Seagen and have 44Billion in cash lol", "score": 1, "replies": []}, {"body": "The market doesn't give a shit about this downgrade. They are reversing their incorrect overweight call, going underperform at what will be the bottom", "score": 1, "replies": []}, {"body": "Who cares about some analyst. Long PFE.", "score": 1, "replies": []}]}
